Chimeric antigen receptor (CAR) T–cell immunotherapy re-engineers a patient's immune cells to target cancer cells. While successful in some types of leukemia, the approach has yet to realize its potential against pediatric ...
Aug 5, 2024
0
0
The U.S. Food and Drug Administration (FDA) has granted accelerated approval for the immunotherapy afamitresgene autoleuecel (Tecelra, also known as afami-cel) for the treatment of adults with a rare soft tissue cancer called ...
Aug 5, 2024
0
0
CAR-T cells are highly effective in treating selected blood cancers. However, challenges remain with this new therapy, which was first approved in 2017 in the U.S. and a year later in Europe for treating acute lymphoblastic ...
Aug 2, 2024
0
1
